Checkpoint inhibitors are among the most promising immunotherapy tools, but what do they actually do? Checkpoint inhibitors work by "releasing the brakes" on the immune system, allowing it to more effectively attack cancer cells.
1. How Immune Checkpoints Work
The immune system has built-in safety switches known as checkpoints that prevent it from attacking normal cells. Cancer cells can use these checkpoints to evade detection.
Two of the most commonly studied characteristics are
-
'PD-1/PD-L1: PD-1 is a receptor on T cells that, when bound to PD-L1 on tumor cells, inhibits the T cell's attack.
-
CTLA-4: Another checkpoint that reduces T cell activation early in the immune response.
2. Mechanism of Checkpoint Inhibitors
Monoclonal antibodies called checkpoint inhibitors are used to prevent these "off switches" from functioning. T cells can remain active for longer periods of time and recognize and kill tumor cells if PD-1 is prevented from binding to PD-L1 or CTLA-4 is blocked.
3. Why They’re Not Universally Effective
-
Tumors may lack sufficient checkpoint molecules for targeting.
-
Some tumors employ alternative immune evasion strategies unrelated to PD-1 or CTLA-4.
-
Immune suppression in the TME can still reduce T cell activity.
4. The Future of Checkpoint Therapy
Researchers are investigating:
-
Combining multiple checkpoint inhibitors to produce stronger responses
-
Combining immunotherapy with radiotherapy, chemotherapy, or TME-modulating drugs
-
Identifying biomarkers that predict which patients will benefit
Key Takeaway
Checkpoint inhibitors have opened up new possibilities in cancer treatment, but their efficacy is dependent on the tumor, the patient's immune system, and the microenvironment. They are effective tools when used in the proper context.